<DOC>
	<DOCNO>NCT01630070</DOCNO>
	<brief_summary>The objective clinical study evaluate immediate long-term ( 12 month ) safety effectiveness Nitinol Self-Expanding Paclitaxel-Eluting stent treatment patient critical limb ischemia ( i.e . rest pain non-healing foot ulcer ) due presence arterial lesion below-the-knee artery maximally 50mm long .</brief_summary>
	<brief_title>Single Arm Study With Nitinol Self-Expanding Paclitaxel-Eluting Stent Treat BTK Arteries</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patient present rest pain minor tissue loss ( Rutherford Clinical Category 4 5 ) Patient willing comply specify followup evaluation specify time Patient &gt; 18 year old Patient understand nature procedure provide write informed consent , prior enrolment study Patient project lifeexpectancy least 12 month Patient eligible treatment SelfExpanding PaclitaxelEluting stent Male , infertile female , female child bear potential practicing acceptable method birth control negative pregnancy test within 7 day prior study procedure Evidence screen ≥50 % de novo lesion ( restenosis previous PTA ) infrapopliteal artery , confirm angiography Reference vessel diameter visually estimate ≥3.0mm ≤4.5mm Identifiable distal target vessel upon completion intervention , anticipate provide reconstitution blood flow foot . Guidewire successfully traverse lesion Length target lesion &lt; 50mm Untreated flowlimiting inflow lesion Perioperative unsuccessful ipsilateral percutaneous vascular procedure treat inflow disease prior enrollment Has previous peripheral bypass affect target limb Major distal amputation ( transmetatarsal ) study limb nonstudy limb Nonatherosclerothic disease result occlusion ( e.g . embolism , Buerger 's disease , vasculitis ) Patient contraindication know untreated allergy antiplatelet therapy , anticoagulant , thrombolytic drug drug anticipate used Patient hypersensitivity contrast device material adequately pretreated Patient know uncontrollable hypercoagulable condition , refuse blood transfusion Life expectancy le 12 month Patient currently participate investigational drug another device study may clinically interfere study endpoint Patient comorbid condition ( ) judgment physician precludes safe percutaneous intervention Has endstage renal disease define undergoing hemodialysis kidney failure Known allergy contrast medium adequately premedicated prior study procedure Patient know hypersensitivity heparin , include patient previous incidence heparininduced thrombocytopenia ( HIT ) type II Treatment ipsilateral nonstudy inflow lesion material regular guidewires , regular PTA balloon , bare metal stent and/or paclitaxelcoated stent Additional treatment study lesion require materials/procedures standard guidewires , regular PTA balloon and/or SelfExpanding PaclitaxelEluting stent ( e.g . thrombectomy , reentry catheter , CTOwires , cut balloon , cryoballoon , etc )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Critical limb ischemia</keyword>
	<keyword>Rest pain</keyword>
	<keyword>Minor tissue loss</keyword>
	<keyword>Below knee</keyword>
</DOC>